Oncology Venture A/S is the drug‑development arm spun out of Medical Prognosis Institute focused on redeveloping failed oncology drugs by conducting targeted‑enrollment clinical trials. Its core product is the DRP (Drug Response Predictor) biomarker platform, which develops tumor‑derived gene signatures to predict patient response; the DRP has been tested in 31 trials (26 showed predictive value), externally validated with MD Anderson collaborators, and patented for over 60 anticancer drugs in the US. OV uses DRP to screen and enroll patients most likely to respond, with the stated aim of raising response rates in phase 2 trials to transform drugs into approvable products. The company says the financing secured this year enables it to fund and run focused phase 2 clinical programs in DRP‑selected patients. Financially, OV has raised a total of 15,547,000 DKK this year and reports a nominal share capital of 2,196,596 DKK. OV also collaborates with partners such as Lantern Pharma on grant‑funded development work for Irofulven.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2015